Advertisement

Topics

Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial.

08:00 EDT 26th March 2018 | BioPortfolio

Summary of "Costs associated with febrile neutropenia in Japanese patients with primary breast cancer: post-hoc analysis of a randomized clinical trial."

Febrile neutropenia (FN), a decrease in blood neutrophils accompanied by fever, is a major adverse event (AE) associated with cancer chemotherapy. We aimed to estimate the direct medical costs associated with FN management in breast cancer patients within a clinical trial with pegfilgrastim, a pegylated form of recombinant granulocyte colony-stimulating factor (G-CSF).

Affiliation

Journal Details

This article was published in the following journal.

Name: Japanese journal of clinical oncology
ISSN: 1465-3621
Pages:

Links

DeepDyve research library

PubMed Articles [25771 Associated PubMed Articles listed on BioPortfolio]

Febrile neutropenia in cancer patients: management in the emergency room.

Febrile neutropenia is a life-threatening condition that requires immediate attention, especially in patients with chemotherapy-related neutropenia. Patients with febrile neutropenia have a much great...

Prophylaxis of Chemotherapy-induced Neutropenia and Febrile Neutropenia with Lipegfilgrastim in Patients with Non-Hodgkin Lymphoma (NADIR study).

The prospective non-interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex ), a glycopegylated granulocyte colony stimu...

Integrative omics to detect bacteremia in patients with febrile neutropenia.

Cancer chemotherapy-associated febrile neutropenia (FN) is a common condition that is deadly when bacteremia is present. Detection of bacteremia depends on culture, which takes days, and no accurate p...

Lipegfilgrastim - long acting G-CSF in prevention of chemotherapy-induced neutropenia.

One of the most dangerous complications of bone marrow suppression due to chemotherapy is febrile neutropenia. The treatment of the affected patients is a multidisciplinary task. In addition to chemot...

 72 h): findings from the MONITOR-GCSF study." class="title">Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Granulocyte colony-stimulating factors (G-CSFs) are indicated for prophylaxis or management of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Guidelines recommend G-CSF 24-72 h ...

Clinical Trials [2191 Associated Clinical Trials listed on BioPortfolio]

Observational And Non-Interventional Study Of Patients With Febrile Neutropenia In Order To Evaluate The Antibacterial Therapeutical Options Conducted In Multiple Centers

The purpose of this study is to define and classify the use of antibacterial agents used in Turkey for febrile neutropenia patients.

Incidence of Febrile Neutropenia

Prospective observational study of febrile neutropenia (FN) and pegfilgrastim primary prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (>20%) FN-risk chemoth...

Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer

This study will assess treatment of febrile neutropenia in subjects in with relapsing or metastatic breast cancer whose risk level for febrile neutropenia is low and who are receiving seco...

Fatigue and Symptom Burden in Febrile Neutropenia

Primary Objectives: - To determine whether fatigue improves as patients are treated for febrile neutropenia (Day #1, Day #2 and Day #6). Secondary Objectives: - T...

Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy

Evaluate the reproducibility and validate a posteriori a new rule of clinical decision on a multi-center population of children with a post-chemotherapy febrile neutropenia

Medical and Biotech [MESH] Definitions

A hematopoietic growth factor which promotes proliferation and maturation of neutrophil granulocytes. Clinically it is effective in decreasing the incidence of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive therapy or in reducing the duration of neutropenia and neutropenia-related clinical sequelae in patients with non-myeloid malignancies undergoing myeloblastive chemotherapy followed by BMT. It has also been used in AIDS patients with CMV retinitis being treated with GANCICLOVIR. (Gelman CR, Rumack BH & Hess AJ (eds): DRUGDEX(R) System. MICROMEDEX, Inc., Englewood, Colorado (Edition expires 11/30/95))

A species of FLAVIVIRUS, one of the Japanese encephalitis virus group (ENCEPHALITIS VIRUSES, JAPANESE), found in Australia and New Guinea. It causes a fulminating viremia resembling Japanese encephalitis (ENCEPHALITIS, JAPANESE).

Fever accompanied by a significant reduction in the number of NEUTROPHILS.

A species of FLAVIVIRUS, one of the Japanese encephalitis virus group (ENCEPHALITIS VIRUSES, JAPANESE), which is the etiological agent of Japanese encephalitis found in Asia, southeast Asia, and the Indian subcontinent.

FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Article